1–3 of 3 results for nr2e3
A Novel Modifier Gene Therapy for Retinitis Pigmentosa: 2-Year Results of a Phase 1/2, Multicenter, Dose-Escalation Study of Subretinal OCU400
Syed Shah, MD
Annual Meeting Talks
2025
One Year Follow-up in a Phase 1/2 Clinical Trial of a Gene Modifier Therapy (OCU400) for the Treatment of Retinitis Pigmentosa
Benjamin Bakall, MD, PhD
2024
Recognizable Patterns of Submacular Fibrosis in the Enhanced S-Cone Syndrome
Sawsan R Nowilaty, MD, FASRS
2021